Digital Commercial Excellence in Pharmaceutical Marketing: A Systematic Review of Omnichannel Engagement and Launch Performance

Background: Following the pandemic-era disruption of field-based promotion, pharmaceutical companies invested heavily in digital and omnichannel commercial models. By 2023 the industry had accumulated enough operating history to ask whether that investment had translated into measurable commercial excellence. Yet the evidence base remained fragmented across peer-reviewed marketing science, health services research, and a large body of vendor-produced industry analytics.

Objectives: This review synthesises the 2023 evidence on three linked questions. First, what is the observed state of omnichannel maturity in pharmaceutical commercial organisations? Second, what does the evidence show about the effectiveness of digital and hybrid customer engagement with healthcare professionals (HCPs)? Third, does omnichannel capability demonstrably improve product launch performance?

Methods: A structured evidence synthesis was conducted following PRISMA 2020 reporting principles and the Tranfield et al. (2003) approach to evidence-informed management review. Peer-reviewed literature was searched in Scopus, Web of Science, PubMed, and Business Source Complete. Industry and grey literature was searched across the published repositories of IQVIA, Veeva, McKinsey, Trinity Life Sciences, L.E.K. Consulting, EPG Health, Indegene, and comparable sources. Records were screened against pre-specified inclusion criteria, appraised using an adapted Mixed Methods Appraisal Tool supplemented by a commercial-independence criterion, and synthesised narratively using thematic analysis.

Results: Three findings dominate. (1) A persistent maturity gap separates aspiration from execution: industry survey evidence from 2023 indicates that although nearly all pharmaceutical executives endorse omnichannel strategy, only about 15 percent of companies characterise their own HCP engagement as genuinely omnichannel, with the remainder operating multichannel or cross-channel models. (2) Coordination, not channel count, carries the effect. The strongest available effect estimates attach to sequencing and integration rather than to digital volume: digital content used inside meetings more than doubles promotional response, and rep interactions followed by a digital exposure within a short window show materially higher prescription conversion. (3) The launch environment tightened rather than eased. The six-month determination window held, most launches continue as they start, and the failures documented are failures of pre-launch planning and cross-functional alignment rather than of execution intensity.

Conclusions: The evidence supports a coordination-centric rather than a channel-centric theory of digital commercial excellence. However, the causal evidence base is weak. The most quantitatively specific findings originate from vendors with a commercial interest in the conclusion, and almost no peer-reviewed study isolates the effect of omnichannel orchestration on launch trajectory using a credible identification strategy. This is the field's principal evidentiary gap.